title: Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part III: leucocyte activation: a new feature for platelet concentrates?
abstract: Platelet-rich fibrin (PRF) belongs to a new generation of platelet concentrates, with simplified processing and without biochemical blood handling. In this third article, we investigate the immune features of this biomaterial. During PRF processing, leucocytes could also secrete cytokines in reaction to the hemostatic and inflammatory phenomena artificially induced in the centrifuged tube. We therefore undertook to quantify 5 significant cell mediators within platelet poor plasma supernatant and PRF clot exudate serum: 3 proinflammatory cytokines (IL-1beta, IL-6, and TNF-alpha), an antiinflammatory cytokine (IL-4), and a key growth promoter of angiogenesis (VEGF). Our data are correlated with that obtained in plasma (nonactivated blood) and in sera (activated blood). These initial analyses revealed that PRF could be an immune regulation node with inflammation retrocontrol abilities. This concept could explain the reduction of postoperative infections when PRF is used as surgical additive.
authors.affiliation: Biophysics Laboratory, Faculty of Dental Surgery, University of Paris V, Paris, France. drdohand@hotmail.com
authors.forename: David M
authors.initials: DM
authors.lastname: Dohan
authors.forename: Joseph
authors.initials: J
authors.lastname: Choukroun
authors.forename: Antoine
authors.initials: A
authors.lastname: Diss
authors.forename: Steve L
authors.initials: SL
authors.lastname: Dohan
authors.forename: Anthony J J
authors.initials: AJ
authors.lastname: Dohan
authors.forename: Jaafar
authors.initials: J
authors.lastname: Mouhyi
authors.forename: Bruno
authors.initials: B
authors.lastname: Gogly
mesh_terms: D000328:Adult; D001792:Blood Platelets / Q000276:immunology*; D016207:Cytokines / Q000097:blood / Q000276:immunology*; D005337:Fibrin / Q000276:immunology*; D015718:Fibrin Tissue Adhesive / Q000494:pharmacology; D005782:Gels; D006490:Hemostatics / Q000494:pharmacology; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood / Q000276:immunology*; D007375:Interleukin-1 / Q000097:blood / Q000276:immunology / Q000378:metabolism; D015847:Interleukin-4 / Q000097:blood / Q000276:immunology / Q000378:metabolism; D015850:Interleukin-6 / Q000097:blood / Q000276:immunology / Q000378:metabolism; D007962:Leukocytes / Q000276:immunology; D008297:Male; D044367:Phase Transition; D010974:Platelet Aggregation / Q000502:physiology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000097:blood / Q000276:immunology; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D016207:Cytokines; D015718:Fibrin Tissue Adhesive; D005782:Gels; D006490:Hemostatics; D018836:Inflammation Mediators; D007375:Interleukin-1; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D042461:Vascular Endothelial Growth Factor A; D015847:Interleukin-4; D005337:Fibrin